Reversion mutations have been reported in circulating tumour DNA of up to 39% of patients with BRCA1/2-mutated prostate cancer after progression on rucaparib, and approximately 24% of patients with ovarian cancer after treatment with platinum chemotherapy and PARPi [14, 15]. This evidence concerns the gene BRCA1 and ovarian cancer.